


### PHARMACEUTICAL 2023



### **MORPHIC**

# Morphic Holding Inc. Rank 21 of 446





#### PHARMACEUTICAL 2023



## Morphic Holding Inc. Rank 21 of 446



The relative strengths and weaknesses of Morphic Holding Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Morphic Holding Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Morphic Holding Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 9.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 235% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	362,182
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,126
Liabilities, Non-Current	2,344
Other Assets	4,288
Other Compr. Net Income	-2,857
Other Expenses	67
Other Liabilities	0
Other Net Income	4,422
Other Revenues	70,808
Property and Equipment	2,119
Research and Development	102,062
Selling, General and Administrative Expense	32,142

Output Variable	Value in 1000 USD
Assets	368,589
Liabilities	19,470
Expenses	134,271
Revenues	70,808
Stockholders Equity	349,119
Net Income	-59,041
Comprehensive Net Income	-60,470
Economic Capital Ratio	278%

